Last reviewed · How we verify

NCT05647525

The Etiology of New-onset Status Epilepticus

Completed Last updated 15 December 2022
What this trial tests

trial testing Perform autoimmune encephalitis titer tests in Status Epilepticus in 60 participants. Completed in 30 September 2022.

Timeline
1 January 2021
Primary endpoint
30 August 2022
30 September 2022

Quick facts

Lead sponsorJie Liu
StatusCompleted
Study typeOBSERVATIONAL
Enrollment60
Start date1 January 2021
Primary completion30 August 2022
Estimated completion30 September 2022
Sites1 location across China

Drugs / interventions tested

Conditions studied

Sponsor

Jie Liu

Who can join

18 and older, any sex, with Status Epilepticus. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study will help to identify the causes of new epilepsy and provide a basis for the development of a rational and standardized diagnosis and treatment plan to reduce the rate of disability and death.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Status Epilepticus

Currently open trials in the same condition.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05647525.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing